Rebiotix Inc., a Ferring Company, is seeking to change the therapeutic landscape with our innovative microbiota-based MRT™ Drug Platform
Unlocking the Potential of Our MRT™ Drug Platform
Our microbiota-based MRT™ drug platform, represents an entirely new approach to the study of challenging diseases. With our MRT drug platform, we could potentially change the therapeutic landscape for challenging diseases, starting with recurrent Clostridioides difficile (C. diff.) infection.
Bringing innovative therapeutics to the market to help patients live better lives is the core of Ferring Pharmaceutical’s vision. Our goal is to continue developing and evaluating formulations under the MRT platform that contribute to Ferring’s vision and add to the company’s long history of serving patients around the world.
Harnessing the Power of the Microbiome for Challenging Diseases
The human gut microbiota, found in the intestinal tract, is the most diverse and dense microbial community.1 It plays an important role in our daily health, influencing metabolism, immunity, digestion, and a host of other functions that contribute to our well-being. If this complex community of organisms experiences a disruption, illness can ensue, which can influence our quality of life.
By leveraging the potential of the human microbiome to investigate this disruption, we can explore the link between health and disease and find new, innovative ways to restore hope to patients. Learn more about the investigational formulations and our vision for the microbiome by visiting our MRT Platform page.
- Thursby E, Juge N. Introduction to the human gut microbiota. Biochemical Journal. 2017;474(11):1823-1836. doi:10.1042/bcj20160510